SANTA CLARA, Calif. & WOBURN, Mass.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) and BioTrove today announced that they have signed a non-exclusive value-added reseller agreement to enable BioTrove to provide an end-to-end solution for mass spectrometry-based drug discovery. This solution will combine technology leader BioTrove’s RapidFire Mass Spectrometry sample preparation system with Agilent’s rugged, accurate mass spectrometers. The reseller agreement expands on an established strategic relationship between Agilent and BioTrove, furthering both companies’ ability to enhance customer workflows.
